Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

News

1 - 10of about 314 News

1 - 10of about 314 News

January 27, 2023

Not intended for U.S. and UK Media

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

January 19, 2023

Bayer launches new collaboration with Oerth Bio to further advance innovations in crop protection

January 10, 2023

Not intended for U.S. and U.K. Media

Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros

December 16, 2022

Not intended for U.S. and UK Media

Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

December 14, 2022

Bayer recognized as leader on climate change for fifth consecutive year

November 11, 2022

Not intended for U.S. and UK Media

Bayer receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity

November 08, 2022

Third quarter of 2022

Bayer with continued strong performance

October 17, 2022

Not intended for U.S. and UK Media

Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy

October 05, 2022

Bayer completes sale of its Environmental Science Professional business to Cinven

September 08, 2022

Not intended for U.S. and UK Media

Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases